Contract 75D30122D14069
Dynavax Technologies Corporation · Department Of Health And Human Services · June 29, 2022
Dynavax Technologies Corporation was awarded a federal contract by Department Of Health And Human Services (Centers For Disease Control And Prevention) on June 29, 2022 for $5.46 million of work in biological product (except diagnostic) manufacturing. It was awarded under full and open competition. The contract has been modified 6 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on July 23, 2024. If all options are exercised, the contract could reach $56.20 million.
Contract details
- PIID
- 75D30122D14069
- Award type
- —
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 325414 · Biological Product (Except Diagnostic) Manufacturing
- Product / service
- Drugs And Biologicals
- First action
- June 29, 2022
- Latest action
- July 23, 2024
Description
VACCINES FOR ADULTS 2022-2023
Modification timeline
-
July 23, 2024Mod P00006$0
-
April 8, 2024Mod P00005$-300
-
May 12, 2023Mod P00004$2.30M
-
March 22, 2023Mod P00003$400.9K
-
October 28, 2022Mod P00002$1.53M
-
August 18, 2022Mod P00001$128.5K
-
June 29, 2022Base award$1.10M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Bio-Rad Laboratories, Inc. | Department Of Health And Human Services | March 31, 2026 | $20.6K |
| Georgia Tech Research Corp | Department Of Health And Human Services | March 28, 2026 | $145.8K |
| Seqirus Inc | Department Of Health And Human Services | March 25, 2026 | $23.7K |
| Seqirus Inc | Department Of Health And Human Services | March 24, 2026 | $0 |
| Battelle Memorial Institute | Department Of Health And Human Services | March 19, 2026 | $2.80M |
| Sanofi Vaccines Us Inc. | Department Of Health And Human Services | March 19, 2026 | $53.21M |
Top contractors in NAICS 325414
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Pfizer Inc | 3 | $15.27B |
| 2 | Sanofi Vaccines Us Inc. | 606 | $9.38B |
| 3 | Regeneron Pharmaceuticals Inc | 1 | $5.57B |
| 4 | Merck Sharp & Dohme Corp. | 56 | $3.99B |
| 5 | Emergent Biodefense Operations Lansing Llc | 16 | $3.34B |
| 6 | Merck Sharp & Dohme Llc | 15 | $3.33B |
| 7 | Pfizer Inc. | 25 | $3.11B |
| 8 | Glaxosmithkline Holdings (Americas) Inc. | 109 | $2.24B |
| 9 | Modernatx, Inc. | 1 | $1.75B |
| 10 | Bavarian Nordic A/S | 1 | $1.01B |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75D30122D14069?
Contract 75D30122D14069 is a federal contract awarded to Dynavax Technologies Corporation by Department Of Health And Human Services on June 29, 2022 for $5.46 million of work classified under BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING. It has been modified 6 times since the base award.
Who won contract 75D30122D14069?
Dynavax Technologies Corporation won contract 75D30122D14069 from Department Of Health And Human Services.
How much is contract 75D30122D14069 worth?
Contract 75D30122D14069 has obligated $5.46 million to date, with a total potential value of $56.20 million if all options are exercised.